Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty.

Autor: Mul, D., Oostdijk, W., Waelkens, J. J. J., Schulpen, T. W. J., Drop, S. L. S.
Předmět:
Zdroj: Clinical Endocrinology; Jul2001, Vol. 55 Issue 1, p121-129, 9p
Abstrakt: BACKGROUND Early onset of puberty is frequently observed in adopted children. During treatment with a gonadotrophin releasing hormone agonist (GnRHa), a decrease in height velocity (HV) precludes height gain. OBJECTIVE AND DESIGN We studied the effect of the addition of GH to GnRHa treatment in a 3-year prospective randomized trial in 30 adopted children with early puberty. PATIENTS Mean age (SD) at start of treatment was 9·6 (0·9) years in girls and predicted adult height (PAH) using a segmented bone age (BA) assessment method was 148·0 (5·3) cm. RESULTS HV decreased gradually in both groups with a higher HV in the group with GH addition (group B). No significant difference between the rates of bone maturation [change in bone age (ΔBA)/change in chronological age (ΔCA)] of both treatment groups was observed. After 3 years of treatment, PAH increase was 5·7 (3·8) cm in group A (GnRHa alone) and 10·1 (3·8) cm in group B (P < 0·01). IGF-I levels were higher in group B. HV decreased slowly in both groups during treatment, unlike stabilization of IGF-I levels. CONCLUSION We conclude that, after 3 years of treatment, the addition of GH to GnRHa results in higher HV and a significant increase in PAH compared to GnRHa alone. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: